Our news journalists obtained a quote from the research from the University of Antwerp Hospital, "We retrospectively selected all adult patients with confirmed H1N1 virus infection admitted to the intensive care unit (ICU) of two tertiary care hospitals from September 2009 to March 2011. Differences in baseline factors, risk factors, and outcome parameters were studied between patients with and without IPA. Of 40 critically ill patients with confirmed H1N1, 9 (23 %) developed IPA 3 days after ICU admission. Five patients had proven and four had probable IPA. Significantly more IPA patients received CS within 7 days before ICU admission (78 versus 23 %, p = 0.002). IPA patients also received significantly higher doses of CS before ICU admission [hydrocortisone equivalent 800 (360-2,635) versus 0 (0-0) mg, p = 0.005]. On multivariate analysis, use of CS before ICU admission was independently associated with IPA [odds ratio (OR) 14.4 (2.0-101.6), p = 0.007]. IPA was diagnosed in 23 % of critically ill patients with H1N1 virus infection after a median of 3 days after ICU admission. Our data suggest that use of CS 7 days before ICU admission is an independent risk factor for fungal superinfection."
According to the news editors, the research concluded: "These findings may have consequences for clinical practice as they point out the need for increased awareness of IPA, especially in those critically ill H1N1 patients already receiving CS."
For more information on this research see: Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Medicine, 2012;38(11):1761-1768. Intensive Care Medicine can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Intensive Care Medicine - www.springerlink.com/content/0342-4642/)
Our news journalists report that additional information may be obtained by contacting J. Wauters, Univ Antwerp Hosp, Intens Care Unit, Antwerp, Belgium.
Keywords for this news article include: Europe, Antwerp, Belgium, Mycoses, Viruses, Virology, Fungal Lung Diseases, Invasive Pulmonary Aspergillosis, Respiratory Tract Diseases and Conditions
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.